Engineered immune cells take on deadly pancreatic cancer in first human trial
NCT ID NCT07153289
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tests a new treatment for advanced pancreatic cancer that has not responded to standard therapies. It uses a patient's own immune cells, modified in a lab to target a protein called CD318 found on cancer cells. The goal is to see if this approach is safe and can shrink tumors or slow the disease. About 38 adults will take part in this early-phase trial across multiple German centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.